Mylan to develop biosimilar alternative to Botox
Mylan NV will roll out a biosimilar medication for Botox in a deal with Revance Therapeutics.
Mylan (Nasdaq: MYL) said it had reached a deal to develop and commercialize a biosimilar for Botox, which is a neuromodulator. Biosimilars are products that are similar biologically or interchangeable with other FDA-approved medication.
The deal calls for Mylan to pay Revance (Nasdaq: RVNC) $25 m illion up front and other payments based on targets and royalties. It's a huge market for Mylan and Revance,…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Paul J. Gough Source Type: news